Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Amir Tahmasb Fathi, M.D.

Co-Author

This page shows the publications co-authored by Amir Fathi and Seth Wander.
Connection Strength

1.996
  1. Combined Targeted Therapy for BRAF-Mutant, Treatment-Related Acute Myeloid Leukemia. JCO Precis Oncol. 2017 Nov; 1:1-7.
    View in: PubMed
    Score: 0.733
  2. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol. 2014 Jun; 5(3):65-77.
    View in: PubMed
    Score: 0.578
  3. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer. 2019 02 15; 125(4):541-549.
    View in: PubMed
    Score: 0.197
  4. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica. 2017 04; 102(4):719-727.
    View in: PubMed
    Score: 0.173
  5. Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. Oncologist. 2016 Feb; 21(2):214-9.
    View in: PubMed
    Score: 0.162
  6. Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia. Semin Hematol. 2015 Jul; 52(3):165-71.
    View in: PubMed
    Score: 0.153
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.